Lactams

"Lactams" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Cyclic AMIDES formed from aminocarboxylic acids by the elimination of water. Lactims are the enol forms of lactams.

Descriptor ID	D007769
MeSH Number(s)	D02.065.589 D03.383.411
Concept/Terms	Lactams Lactams Lactims Lactims

Below are MeSH descriptors whose meaning is more general than "Lactams".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Amides [D02.065]
Lactams [D02.065.589]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Lactams [D03.383.411]

Below are MeSH descriptors whose meaning is more specific than "Lactams".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Lactams" by people in this website by year, and whether "Lactams" was a major or minor topic of these publications.

Bar chart showing 13 publications over 9 distinct years, with a maximum of 4 publications in 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	0	1	1
2009	1	0	1
2010	1	0	1
2012	0	1	1
2017	1	0	1
2022	0	1	1
2023	0	4	4
2024	0	1	1
2025	0	2	2

Below are the most recent publications written about "Lactams" by people in Profiles.

Maryam A, Moquin SA, Dovala D, Kaur J, Kurt Yilmaz N, Shaqra AM, Schiffer CA. Structural Analysis of Inhibitor Binding to the Feline Enteric Coronavirus (FECV) Main Protease. Viruses. 2025 Nov 16; 17(11).

View in: PubMed
Zvornicanin SN, Shaqra AM, Flynn J, Carias Martinez H, Jia W, Moquin S, Dovala D, Bolon DN, Kurt Yilmaz N, Schiffer CA. Molecular mechanisms of drug resistance and compensation in SARS-CoV-2 main protease: the interplay between E166 and L50. mBio. 2025 May 14; 16(5):e0406824.

View in: PubMed
Flynn JM, Zvornicanin SN, Tsepal T, Shaqra AM, Kurt Yilmaz N, Jia W, Moquin S, Dovala D, Schiffer CA, Bolon DNA. Contributions of Hyperactive Mutations in Mpro from SARS-CoV-2 to Drug Resistance. ACS Infect Dis. 2024 04 12; 10(4):1174-1184.

View in: PubMed
Edelstein GE, Boucau J, Uddin R, Marino C, Liew MY, Barry M, Choudhary MC, Gilbert RF, Reynolds Z, Li Y, Tien D, Sagar S, Vyas TD, Kawano Y, Sparks JA, Hammond SP, Wallace Z, Vyas JM, Barczak AK, Lemieux JE, Li JZ, Siedner MJ. SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study. Ann Intern Med. 2023 12; 176(12):1577-1585.

View in: PubMed
Faust JS, Kumar A, Shah J, Khadke S, Dani SS, Ganatra S, Sax PE. Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18-50 Years. Clin Infect Dis. 2023 11 11; 77(9):1257-1264.

View in: PubMed
Flynn JM, Huang QYJ, Zvornicanin SN, Schneider-Nachum G, Shaqra AM, Yilmaz NK, Moquin SA, Dovala D, Schiffer CA, Bolon DNA. Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease. ACS Infect Dis. 2023 07 14; 9(7):1372-1386.

View in: PubMed
Boucau J, Uddin R, Marino C, Regan J, Flynn JP, Choudhary MC, Chen G, Stuckwisch AM, Mathews J, Liew MY, Singh A, Reynolds Z, Iyer SL, Chamberlin GC, Vyas TD, Vyas JM, Turbett SE, Li JZ, Lemieux JE, Barczak AK, Siedner MJ. Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. 2023 02 08; 76(3):e526-e529.

View in: PubMed
Singh N, Temin S, Baker S, Blanchard E, Brahmer JR, Celano P, Duma N, Ellis PM, Elkins IB, Haddad RY, Hesketh PJ, Jain D, Johnson DH, Leighl NB, Mamdani H, Masters G, Moffitt PR, Phillips T, Riely GJ, Robinson AG, Rosell R, Schiller JH, Schneider BJ, Spigel DR, Jaiyesimi IA. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline. J Clin Oncol. 2022 10 01; 40(28):3310-3322.

View in: PubMed
Li CS, Sarotti AM, Huang P, Dang UT, Hurdle JG, Kondratyuk TP, Pezzuto JM, Turkson J, Cao S. NF-?B inhibitors, unique ?-pyranol-?-lactams with sulfide and sulfoxide moieties from Hawaiian plant Lycopodiella cernua derived fungus Paraphaeosphaeria neglecta FT462. Sci Rep. 2017 09 05; 7(1):10424.

View in: PubMed
Romano KP, Ali A, Aydin C, Soumana D, Ozen A, Deveau LM, Silver C, Cao H, Newton A, Petropoulos CJ, Huang W, Schiffer CA. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog. 2012; 8(7):e1002832.

View in: PubMed

People

Explore

Similar Concepts

Top Journals